296 related articles for article (PubMed ID: 25825497)
1. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
Zhang B; Liao L; Wu F; Zhang F; Sun Z; Chen H; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127598. PubMed ID: 33011288
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.
Olsen JB; Cao XJ; Han B; Chen LH; Horvath A; Richardson TI; Campbell RM; Garcia BA; Nguyen H
Mol Cell Proteomics; 2016 Mar; 15(3):892-905. PubMed ID: 26750096
[TBL] [Abstract][Full Text] [Related]
5. Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation.
Wang L; Li L; Zhang H; Luo X; Dai J; Zhou S; Gu J; Zhu J; Atadja P; Lu C; Li E; Zhao K
J Biol Chem; 2011 Nov; 286(44):38725-38737. PubMed ID: 21880715
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of substrate methylation and inhibition of SMYD2.
Ferguson AD; Larsen NA; Howard T; Pollard H; Green I; Grande C; Cheung T; Garcia-Arenas R; Cowen S; Wu J; Godin R; Chen H; Keen N
Structure; 2011 Sep; 19(9):1262-73. PubMed ID: 21782458
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.
Eggert E; Hillig RC; Koehr S; Stöckigt D; Weiske J; Barak N; Mowat J; Brumby T; Christ CD; Ter Laak A; Lang T; Fernandez-Montalvan AE; Badock V; Weinmann H; Hartung IV; Barsyte-Lovejoy D; Szewczyk M; Kennedy S; Li F; Vedadi M; Brown PJ; Santhakumar V; Arrowsmith CH; Stellfeld T; Stresemann C
J Med Chem; 2016 May; 59(10):4578-600. PubMed ID: 27075367
[TBL] [Abstract][Full Text] [Related]
8. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
Xu S; Zhong C; Zhang T; Ding J
J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.
Cowen SD; Russell D; Dakin LA; Chen H; Larsen NA; Godin R; Throner S; Zheng X; Molina A; Wu J; Cheung T; Howard T; Garcia-Arenas R; Keen N; Pendleton CS; Pietenpol JA; Ferguson AD
J Med Chem; 2016 Dec; 59(24):11079-11097. PubMed ID: 28002961
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into estrogen receptor α methylation by histone methyltransferase SMYD2, a cellular event implicated in estrogen signaling regulation.
Jiang Y; Trescott L; Holcomb J; Zhang X; Brunzelle J; Sirinupong N; Shi X; Yang Z
J Mol Biol; 2014 Oct; 426(20):3413-25. PubMed ID: 24594358
[TBL] [Abstract][Full Text] [Related]
11. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Yi X; Jiang XJ; Fang ZM
Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the Substrate Specificity of the SMYD2 Protein Lysine Methyltransferase and Discovery of Novel Non-Histone Substrates.
Weirich S; Schuhmacher MK; Kudithipudi S; Lungu C; Ferguson AD; Jeltsch A
Chembiochem; 2020 Jan; 21(1-2):256-264. PubMed ID: 31612581
[TBL] [Abstract][Full Text] [Related]
13. Repression of p53 activity by Smyd2-mediated methylation.
Huang J; Perez-Burgos L; Placek BJ; Sengupta R; Richter M; Dorsey JA; Kubicek S; Opravil S; Jenuwein T; Berger SL
Nature; 2006 Nov; 444(7119):629-32. PubMed ID: 17108971
[TBL] [Abstract][Full Text] [Related]
14. Smyd2 conformational changes in response to p53 binding: role of the C-terminal domain.
Chandramouli B; Melino G; Chillemi G
Mol Oncol; 2019 Jun; 13(6):1450-1461. PubMed ID: 31069954
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma.
Komatsu S; Imoto I; Tsuda H; Kozaki KI; Muramatsu T; Shimada Y; Aiko S; Yoshizumi Y; Ichikawa D; Otsuji E; Inazawa J
Carcinogenesis; 2009 Jul; 30(7):1139-46. PubMed ID: 19423649
[TBL] [Abstract][Full Text] [Related]
16. Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.
Rubio-Tomás T
Mol Biol Rep; 2021 Nov; 48(11):7499-7508. PubMed ID: 34510321
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of histone and p53 methyltransferase SmyD2 reveal a conformational flexibility of the autoinhibitory C-terminal domain.
Jiang Y; Sirinupong N; Brunzelle J; Yang Z
PLoS One; 2011; 6(6):e21640. PubMed ID: 21738746
[TBL] [Abstract][Full Text] [Related]
18. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase.
Abu-Farha M; Lambert JP; Al-Madhoun AS; Elisma F; Skerjanc IS; Figeys D
Mol Cell Proteomics; 2008 Mar; 7(3):560-72. PubMed ID: 18065756
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the Role of SMYD2 and Its Inhibitor (LLY-507) in the Treatment of Chemically Induced Non-Small Cell Lung Cancer (NSCLC) by Using Fe
Munawwar A; Sajjad A; Rasul A; Sattar M; Jabeen F
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513898
[TBL] [Abstract][Full Text] [Related]
20. SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency.
Boehm D; Jeng M; Camus G; Gramatica A; Schwarzer R; Johnson JR; Hull PA; Montano M; Sakane N; Pagans S; Godin R; Deeks SG; Krogan NJ; Greene WC; Ott M
Cell Host Microbe; 2017 May; 21(5):569-579.e6. PubMed ID: 28494238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
